Heggen, E <br/><br/>
Smoking cessation improves cardiometabolic risk in overweight and obese subjects treated with varenicline and dietary counseling.  [electronic resource] 

 -  Nutrition, metabolism, and cardiovascular diseases : NMCD  Apr 2017 
 - 335-341 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1590-3729 
<br/><br/><label>Standard No.: </label>10.1016/j.numecd.2016.12.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Biomarkers--blood<br/>Blood Pressure<br/>Counseling<br/>Female<br/>Humans<br/>Insulin Resistance<br/>Male<br/>Metabolic Syndrome--diagnosis<br/>Middle Aged<br/>Nicotinic Agonists--adverse effects<br/>Norway--epidemiology<br/>Obesity--blood<br/>Prevalence<br/>Risk Assessment<br/>Risk Factors<br/>Smoking--adverse effects<br/>Smoking Cessation--methods<br/>Smoking Prevention<br/>Time Factors<br/>Treatment Outcome<br/>Triglycerides--blood<br/>Varenicline--adverse effects<br/>Weight Loss